<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313647</url>
  </required_header>
  <id_info>
    <org_study_id>MEXVT</org_study_id>
    <nct_id>NCT04313647</nct_id>
  </id_info>
  <brief_title>A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers</brief_title>
  <official_title>A Tolerance Clinical Study On Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers&#xD;
      with the abundance of adhesive proteins that readily interact with cellular membranes. These&#xD;
      vesicles have a content that includes cytokines and growth factors, signaling lipids, mRNAs,&#xD;
      and regulatory miRNAs. Exosomes are involved in cell-to-cell communication, cell signaling,&#xD;
      and altering cell or tissue metabolism at short or long distances in the body, and can&#xD;
      influence tissue responses to injury, infection, and disease.&#xD;
&#xD;
      Experimental studies have demonstrated that mesenchymal stem cells (MSCs) or their exosomes&#xD;
      (MSCs-Exo) significantly reduced lung inflammation and pathological impairment resulting from&#xD;
      different types of lung injury. In addition, macrophage phagocytosis, bacterial killing and&#xD;
      outcome were improved. It is highly likely that MSCs-Exo have the similar therapeutic effect&#xD;
      on inoculation pneumonia as MSCs themselves.&#xD;
&#xD;
      This clinical study will be performed to evaluate the safety and tolerance of aerosol&#xD;
      inhalation of the exosomes derived from allogenic adipose mesenchymal stem cells (MSCs-Exo)&#xD;
      in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental studies have demonstrated that mesenchymal stem cells (MSCs) or their exosomes&#xD;
      (MSCs-Exo) significantly reduced lung inflammation and pathological impairment resulting from&#xD;
      different types of lung injury. In addition, macrophage phagocytosis, bacterial killing and&#xD;
      outcome were improved. It is highly likely that MSCs-Exo have the similar therapeutic effect&#xD;
      on inoculation pneumonia as MSCs themselves.&#xD;
&#xD;
      Although human bone marrow MSCs have been safely administered in patients with ARDS and&#xD;
      septic shock (phase I/II trials), it seems safer to deliver MSCs-Exo rather than live MSCs.&#xD;
      The intravenous administration of MSCs may result in aggregating or clumping in the injured&#xD;
      microcirculation and carries the risk of mutagenicity and oncogenicity, which do not exist by&#xD;
      treating with nebulized MSCs-Exo. Another advantage of MSCs-Exo over MSCs is the possibility&#xD;
      of storing them for several weeks/months allowing their safe transportation and delayed&#xD;
      therapeutic use.&#xD;
&#xD;
      The purpose of this study, therefore, is to explore the safety and efficiency as well as&#xD;
      provide a clinical dose reference for the subsequent trails of aerosol inhalation of MSCs-Exo&#xD;
      in the treatment of severe lung diseases (including severe lung infection, acute respiratory&#xD;
      distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD), etc.)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MSCs-exosomes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)</measure>
    <time_frame>from Day 0 to Day 7</time_frame>
    <description>Safety evaluation within 7 days after first treatment, including frequency of adverse reaction (AE) and severe adverse reaction (SAE)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Alanine Aminotransferase (ALT) (IU/L)</measure>
    <time_frame>day 0 and day 7</time_frame>
    <description>one of the indexes about liver function</description>
  </other_outcome>
  <other_outcome>
    <measure>Creatinine (Cr) (μmol/L)</measure>
    <time_frame>day 0 and day 7</time_frame>
    <description>One of the indexes about kidney function</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1X level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2X level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4X level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6X level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8X level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1X level of MSCs-Exo</intervention_name>
    <description>Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)</description>
    <arm_group_label>1X level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2X level of MSCs-Exo</intervention_name>
    <description>Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)</description>
    <arm_group_label>2X level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4X level of MSCs-Exo</intervention_name>
    <description>Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)</description>
    <arm_group_label>4X level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>6X level of MSCs-Exo</intervention_name>
    <description>Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)</description>
    <arm_group_label>6X level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>8X level of MSCs-Exo</intervention_name>
    <description>Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)</description>
    <arm_group_label>8X level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers.&#xD;
&#xD;
          2. Age: 19-45, males and females.&#xD;
&#xD;
          3. The weight is within ± 10% of the standard weight [standard weight (kg) = 0.7 ×&#xD;
             (height cm-80)].&#xD;
&#xD;
          4. Examination indices of heart, liver, kidney and blood are all within the normal range.&#xD;
&#xD;
          5. According to Good Clinical Practice (GCP), volunteers who understand and voluntarily&#xD;
             sign the consent form before this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women in pregnancy or lactation.&#xD;
&#xD;
          2. Primary diseases of important organs.&#xD;
&#xD;
          3. Mentally or physically disabled patients.&#xD;
&#xD;
          4. Suspected or definite history of alcohol and drug abuse.&#xD;
&#xD;
          5. According to the investigator's judgment, there is a low possibility of enrollment&#xD;
             (such as frailty, etc.).&#xD;
&#xD;
          6. Volunteers who are allergic to the components of this medicine, or have a history of&#xD;
             allergies to two or more drugs or food.&#xD;
&#xD;
          7. Volunteers who have diseases (such as insomnia) and are using other preventive and&#xD;
             therapeutic drugs before this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieming Qu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <results_first_submitted>December 16, 2020</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>exosomes</keyword>
  <keyword>mesh nebulizer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT04313647/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="P2">
          <title>2X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="P3">
          <title>4X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="P4">
          <title>6X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="P5">
          <title>8X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="B2">
          <title>2X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="B3">
          <title>4X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="B4">
          <title>6X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="B5">
          <title>8X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="25" upper_limit="34"/>
                    <measurement group_id="B2" value="26" lower_limit="24" upper_limit="27"/>
                    <measurement group_id="B3" value="25" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="B4" value="25" lower_limit="24" upper_limit="29"/>
                    <measurement group_id="B5" value="25.5" lower_limit="24" upper_limit="27"/>
                    <measurement group_id="B6" value="25" lower_limit="21" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)</title>
        <description>Safety evaluation within 7 days after first treatment, including frequency of adverse reaction (AE) and severe adverse reaction (SAE)</description>
        <time_frame>from Day 0 to Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O2">
            <title>2X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O3">
            <title>4X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O4">
            <title>6X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O5">
            <title>8X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE)</title>
          <description>Safety evaluation within 7 days after first treatment, including frequency of adverse reaction (AE) and severe adverse reaction (SAE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Alanine Aminotransferase (ALT) (IU/L)</title>
        <description>one of the indexes about liver function</description>
        <time_frame>day 0 and day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O2">
            <title>2X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O3">
            <title>4X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O4">
            <title>6X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O5">
            <title>8X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) (IU/L)</title>
          <description>one of the indexes about liver function</description>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="O2" value="21" lower_limit="8" upper_limit="30"/>
                    <measurement group_id="O3" value="24" lower_limit="14.25" upper_limit="42"/>
                    <measurement group_id="O4" value="17.5" lower_limit="9.75" upper_limit="21.25"/>
                    <measurement group_id="O5" value="15.5" lower_limit="13.25" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="16" upper_limit="21"/>
                    <measurement group_id="O2" value="24" lower_limit="9" upper_limit="24"/>
                    <measurement group_id="O3" value="23.5" lower_limit="13.25" upper_limit="58.25"/>
                    <measurement group_id="O4" value="16" lower_limit="11.75" upper_limit="23.75"/>
                    <measurement group_id="O5" value="15.5" lower_limit="11" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Creatinine (Cr) (μmol/L)</title>
        <description>One of the indexes about kidney function</description>
        <time_frame>day 0 and day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O2">
            <title>2X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O3">
            <title>4X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O4">
            <title>6X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)</description>
          </group>
          <group group_id="O5">
            <title>8X Level</title>
            <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine (Cr) (μmol/L)</title>
          <description>One of the indexes about kidney function</description>
          <units>μmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="64" upper_limit="86"/>
                    <measurement group_id="O2" value="83" lower_limit="57" upper_limit="106"/>
                    <measurement group_id="O3" value="82.5" lower_limit="62.75" upper_limit="90"/>
                    <measurement group_id="O4" value="74.5" lower_limit="59" upper_limit="95"/>
                    <measurement group_id="O5" value="81" lower_limit="56" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="59" upper_limit="86"/>
                    <measurement group_id="O2" value="77" lower_limit="67" upper_limit="115"/>
                    <measurement group_id="O3" value="86" lower_limit="63.25" upper_limit="92.75"/>
                    <measurement group_id="O4" value="74.5" lower_limit="64.75" upper_limit="86.25"/>
                    <measurement group_id="O5" value="80" lower_limit="56.5" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)&#xD;
1X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="E2">
          <title>2X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)&#xD;
2X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (4.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="E3">
          <title>4X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)&#xD;
4X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (8.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="E4">
          <title>6X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)&#xD;
6X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (12.0*10E8 nano vesicles/3 ml)</description>
        </group>
        <group group_id="E5">
          <title>8X Level</title>
          <description>Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)&#xD;
8X level of MSCs-Exo: Once aerosol inhalation of MSCs-derived exosomes (16.0*10E8 nano vesicles/3 ml)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <description>Two subjects developed sinus bradycardia (58bpm, 59bpm) on the seventh day after nebulization according to EKG: one is in 1X group; the other is in 8X group.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Qu</name_or_title>
      <organization>Ruijin Hospital , Shanghai Jiao Tong University School of Medicine</organization>
      <phone>(+86)2164370045</phone>
      <email>jmqu0906@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

